Aytu BioPharma Yönetim
Yönetim kriter kontrolleri 3/4
Aytu BioPharma CEO'su Josh Disbrow, Apr2015 tarihinde atandı, in görev süresi 11.25 yıldır. in toplam yıllık tazminatı $ 883.93K olup, şirket hissesi ve opsiyonları dahil olmak üzere 66.7% maaş ve 33.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.93% ine doğrudan sahiptir ve bu hisseler $ 459.99K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.7 yıl ve 10 yıldır.
Anahtar bilgiler
Josh Disbrow
İcra Kurulu Başkanı
US$883.9k
Toplam tazminat
| CEO maaş yüzdesi | 66.75% |
| CEO görev süresi | 11.3yrs |
| CEO sahipliği | 1.9% |
| Yönetim ortalama görev süresi | 3.7yrs |
| Yönetim Kurulu ortalama görev süresi | 10yrs |
Son yönetim güncellemeleri
Analiz Makalesi • May 14
We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation
Key Insights Aytu BioPharma will host its Annual General Meeting on 21st of May Total pay for CEO Josh Disbrow includes...Analiz Makalesi • Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year
Key Insights Aytu BioPharma will host its Annual General Meeting on 26th of June Salary of US$590.0k is part of CEO...Recent updates
Anlatı Güncellemesi • Jun 26
AYTU: Higher Margins And Lower P/E Will Support Future Upside
Aytu BioPharma’s analyst price target has shifted from $12.50 to $14.50, with analysts pointing to updated assumptions for higher revenue growth, stronger profit margins, and a lower future P/E multiple as key drivers of the new outlook. What's in the News No recent company specific news items were identified for Aytu BioPharma from the provided sources.Analiz Makalesi • Dec 20
Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have had a really impressive month, gaining 28% after a shaky period...Analiz Makalesi • Nov 17
Aytu BioPharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) came out with its quarterly results last week, and we wanted to see how the...Analiz Makalesi • Oct 30
There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted Revenues Despite A 27% Share Price Rise
Those holding Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares would be relieved that the share price has rebounded 27% in...Analiz Makalesi • Jul 29
Improved Revenues Required Before Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock's 25% Jump Looks Justified
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have continued their recent momentum with a 25% gain in the last month...Analiz Makalesi • May 14
We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation
Key Insights Aytu BioPharma will host its Annual General Meeting on 21st of May Total pay for CEO Josh Disbrow includes...Analiz Makalesi • May 04
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 27% in...Analiz Makalesi • Jan 18
Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders are no doubt pleased to see that the share price has bounced 28% in...Analiz Makalesi • Nov 15
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%
To the annoyance of some shareholders, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares are down a considerable 32% in the...Analiz Makalesi • Nov 01
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year
Key Insights Aytu BioPharma will host its Annual General Meeting on 26th of June Salary of US$590.0k is part of CEO...Analiz Makalesi • Jun 14
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) just released its latest quarterly results and things are looking bullish. Results...Analiz Makalesi • Feb 16
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shares have been powering on, with a gain of 25% in...Analiz Makalesi • Jan 23
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Sep 29
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders have had their patience rewarded with a 59% share price jump in the...Seeking Alpha • Oct 13
Aytu stock falls amid suspending clinical programs to save costs
Aytu BioPharma (NASDAQ:AYTU) stock dipped ~5% on Oct. 13 after the company said it was indefinitely suspending certain clinical development programs, thus expecting to save over $20M. The suspension includes AR101/enzastaurin for treat Vascular Ehlers-Danlos Syndrome (VEDS), Healight, and NT0502. Aytu is expecting to generate positive quarterly adjusted EBITDA in H1 calendar year 2023. "This strategic realignment enables us to dedicate our resources to growing our prescription and consumer health segments. Coupled with the suspension of clinical development activities and continued execution against our previously planned $15 million cost cutting program, this shift enables the Company to achieve near-term positive Adjusted EBITDA," said Aytu CEO Josh Disbrow in an Oct. 13 press release. The company expects to provide a detailed financial outlook of its strategy at its quarterly investors call scheduled for mid-November.Seeking Alpha • Sep 27
Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Aytu BioScience press release (NASDAQ:AYTU): FQ4 GAAP EPS of -$0.49 misses by $0.12. Revenue of $27.45M (+16.9% Y/Y) beats by $1.95M. Cash and cash equivalents at the end of the fiscal year ended June 30, 2022 were $19.4 million. Subsequent to the end of the year, the Company raised $10.0 million in gross proceeds in a registered public offering. Prescription segment Adjusted EBITDA was a positive $1.1 million, while Consumer Health was $(2.1) million resulting in a combined Adjusted EBITDA of $(1.0) million for the Company's commercial business. This compares to Adjusted EBITDA of $(5.5) million for the Prescription segment and $(2.7) million for the Consumer Health segment in Q4 2021, resulting in a combined Adjusted EBITDA of $(8.2) million for the Company's commercial business. Shares +5.26%.Seeking Alpha • Sep 14
Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Aytu BioPharma (NASDAQ:AYTU) announced on Wednesday the addition of a fourth patent for AR101/Enzastaurin to treat Vascular Ehlers-Danlos Syndrome, rare genetic disorder treatment. The patent has an expiry date of September 2041. The company expects to advance the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023. "Adding this fourth patent to the portfolio deepens and broadens the intellectual property surrounding AR101/Enzastaurin for the treatment of inherited vascular disorders, including VEDS, for which we are advancing AR101 as an initial indication," the company said. Vascular Ehlers-Danlos syndrome (vEDS) is the most severe type of a hereditary disorder of the connective tissue. (AYTU) had risen 3.3% before the bell.Seeking Alpha • Aug 16
Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aytu BioPharma (NASDAQ:AYTU) said the U.S. Patent and Trademark Office issued a patent, a first for AR101/Enzastaurin. The U.S. patent No. 11,273,148 titled 'Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition,' covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGFβ genes, including Ehlers-Danlos Syndrome, the company said in an Aug. 16 press release. Aytu added that it was the first issued patent supporting the portfolio and expires in August of 2038, if not extended. "This issued patent underpins the broad potential clinical application across numerous inherited vascular disorders, including vascular Ehlers-Danlos Syndrome ("VEDS"), for which we are advancing AR101 as an initial indication. We expect to progress the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023," said Aytu CEO Josh Disbrow. AYTU +0.59% to $0.29 premarket Aug. 16Seeking Alpha • Aug 09
Aytu BioPharma plunges on pricing $10M stock and warrants offering
Aytu BioPharma (NASDAQ:AYTU) priced its underwritten public offering of 21.5M shares to certain investors, pre-funded warrants to purchase 1.75M shares and accompanying warrants to purchase 23.2M shares,. The combined public offering price for each share of common stock and accompanying common warrant is $0.43 and combined offering price for each pre-funded warrant and accompanying common warrant is $0.429. Gross proceeds are expected to be ~$10M. Offer is expected to close on Aug.11. Net proceeds to be used for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome, for growth of the company's commercial business, and for working capital and general corporate purposes.Analiz Makalesi • May 19
Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00
It's been a pretty great week for Aytu BioPharma, Inc. ( NASDAQ:AYTU ) shareholders, with its shares surging 18% to...Analiz Makalesi • Sep 11
Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$34m |
| Dec 31 2025 | n/a | n/a | -US$25m |
| Sep 30 2025 | n/a | n/a | -US$13m |
| Jun 30 2025 | US$884k | US$590k | -US$14m |
| Mar 31 2025 | n/a | n/a | US$2m |
| Dec 31 2024 | n/a | n/a | -US$4m |
| Sep 30 2024 | n/a | n/a | -US$4m |
| Jun 30 2024 | US$928k | US$590k | -US$13m |
| Mar 31 2024 | n/a | n/a | -US$12m |
| Dec 31 2023 | n/a | n/a | -US$17m |
| Sep 30 2023 | n/a | n/a | -US$24m |
| Jun 30 2023 | US$708k | US$590k | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | n/a | n/a | -US$77m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | US$590k | US$590k | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$84m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | US$6m | US$545k | -US$58m |
| Mar 31 2021 | n/a | n/a | -US$42m |
| Dec 31 2020 | n/a | n/a | -US$22m |
| Sep 30 2020 | n/a | n/a | -US$13m |
| Jun 30 2020 | US$2m | US$608k | -US$14m |
Tazminat ve Piyasa: Josh 'nin toplam tazminatı ($USD 883.93K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 655.15K ).
Tazminat ve Kazançlar: Josh 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Josh Disbrow (51 yo)
11.3yrs
Görev süresi
US$883,928
Tazminat
Mr. Joshua R. Disbrow, also known as Josh, serves as Chief Executive Officer at Aytu Biopharma, Inc. since April 16, 2015 and served as its Chairman until 2024. He served as President at Aytu Biopharma, In...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 11.3yrs | US$883.93k | 1.93% $ 460.0k | |
| CFO, Corporate Secretary & Treasurer | 1.7yrs | US$538.65k | 0.46% $ 110.4k | |
| Chief Business Officer | 3.7yrs | US$549.25k | 0.57% $ 136.7k | |
| Chief Commercial Officer | 4.5yrs | US$522.08k | 0.34% $ 80.1k | |
| Vice President of Operations | no data | Veri yok | Veri yok | |
| Senior Vice President of Scientific Affairs | 1.1yrs | Veri yok | Veri yok |
3.7yrs
Ortalama Görev Süresi
49yo
Ortalama Yaş
Deneyimli Yönetim: AYTU 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.7 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 10.5yrs | US$883.93k | 1.93% $ 460.0k | |
| Independent Director | 4yrs | US$87.76k | 0.18% $ 44.0k | |
| Independent Chairman | 10yrs | US$117.76k | 0.13% $ 30.6k | |
| Independent Director | 10.3yrs | US$82.76k | 0.20% $ 47.0k | |
| Independent Director | 3.1yrs | US$77.76k | 0.18% $ 43.3k |
10.0yrs
Ortalama Görev Süresi
59yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AYTU 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/16 18:20 |
| Gün Sonu Hisse Fiyatı | 2026/07/16 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/06/30 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Aytu BioPharma, Inc. 5 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |
| Thomas Flaten | Lake Street Capital Markets, LLC |